Treatment(s) now being considered-Biological therapy Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Biological therapy Posts on Medivizor

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Posted by on Oct 9, 2021 in Lung cancer | 0 comments

In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).   Some background Immunotherapy is a type of cancer treatment that makes use of the immune...

Read More

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Is cancer treatment with immune checkpoint inhibitors associated with infection risk?

Posted by on Oct 9, 2021 in Melanoma | 0 comments

In a nutshell This study is aimed to evaluate the risk of infection for patients who are treated with immune checkpoint inhibitors (ICI) for solid tumors. The study concluded that in frail patients, ICI therapy alone is safer compared to chemotherapy (CT).   Some background Immunotherapy is a type of cancer treatment that makes use of the...

Read More

Evaluating the effectiveness and safety of SOX+bevacizumab or cetuximab for the treatment of patients with advanced colorectal cancer with wild-type KRAS.

Evaluating the effectiveness and safety of SOX+bevacizumab or cetuximab for the treatment of patients with advanced colorectal cancer with wild-type KRAS.

Posted by on Sep 26, 2021 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of S-1 (tegafur/gimeracil/oteracil) and oxaliplatin (Eloxatin) combined with bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with previously untreated advanced colorectal cancer with wild-type KRAS. This study concluded that the safety and effectiveness of...

Read More

Clarithromycin administered daily reduces the skin-related side effects associated with panitumumab treatment for metastatic colorectal cancer.

Clarithromycin administered daily reduces the skin-related side effects associated with panitumumab treatment for metastatic colorectal cancer.

Posted by on Sep 5, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of preventative antibiotic treatment with clarithromycin (Biaxin) to prevent skin-related side effects associated with panitumumab (Vectibix) treatment for patients with metastatic colorectal cancer (mCRC). The data showed that clarithromycin administered daily along with a simple...

Read More

Could patient-reported outcomes predict survival benefits in patients with advanced breast cancer treated with abemaciclib?

Could patient-reported outcomes predict survival benefits in patients with advanced breast cancer treated with abemaciclib?

Posted by on Jun 13, 2021 in Breast cancer | 0 comments

In a nutshell This study evaluated the association between patient-reported outcomes (PROs) and survival outcomes in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (BC) treated with abemaciclib (Verzenio). The data showed that the PROs could be a predictor of survival benefits in these patients. Some...

Read More

Is C-reactive protein associated with survival in patients with non-small cell lung cancer treated with atezolizumab?

Is C-reactive protein associated with survival in patients with non-small cell lung cancer treated with atezolizumab?

Posted by on Apr 25, 2021 in Lung cancer | 0 comments

In a nutshell This study was carried out to see whether a reduction in inflammatory marker C-reactive protein (CRP) following treatment with atezolizumab (Tecentriq) is associated with an improved survival in patients with non-small cell lung cancer (NSCLC). The authors found that a lower CRP following treatment was associated with improved...

Read More

Should immunotherapy and radiotherapy be considered as an effective treatment for non-small cell lung cancer?

Should immunotherapy and radiotherapy be considered as an effective treatment for non-small cell lung cancer?

Posted by on Apr 3, 2021 in Lung cancer | 0 comments

In a nutshell This article analyzed the safety and effectiveness of an immunotherapy (IT) and radiotherapy (RT) combination to treat patients with non-small cell lung cancer (NSCLC). The authors found that combination therapy using an immunotherapy drug such as PD-1/PD-L1 inhibitors and RT may improve the outcomes of these patients. Some background...

Read More

How does durvalumab impact the treatment of unresectable stage III non-small cell lung cancer based on previous treatment?

How does durvalumab impact the treatment of unresectable stage III non-small cell lung cancer based on previous treatment?

Posted by on Mar 14, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the outcomes of durvalumab (Imfinzi) in patients with unresectable (cannot be surgically removed) stage 3 non-small cell lung cancer (NSCLC) who received different combinations of chemoradiotherapy (CRT) previously. The authors found that the use of durvalumab improved survival in all patients previously treated...

Read More

FOLFOXIRI-bevacizumab or FOLFOX-panitumumab for the treatment of left-sided metastatic colorectal cancer without RAS/BRAF mutations.

FOLFOXIRI-bevacizumab or FOLFOX-panitumumab for the treatment of left-sided metastatic colorectal cancer without RAS/BRAF mutations.

Posted by on Jan 24, 2021 in Colorectal cancer | 0 comments

In a nutshell This study compared the use of chemotherapy and bevacizumab (Avastin) or panitumumab (Vectibix) for the treatment of left-sided metastatic colorectal cancer (mCRC) without BRAF/RAS mutations (permanent changes in genes). The study found that both treatment options are effective for these patients.  Some background Patients who...

Read More

Does continuous nivolumab improve outcomes in advanced non-small cell lung cancer?

Does continuous nivolumab improve outcomes in advanced non-small cell lung cancer?

Posted by on Jan 10, 2021 in Lung cancer | 0 comments

In a nutshell This study compared 1-year fixed-duration versus continuous nivolumab (Opdivo) for the treatment of previously treated advanced non-small-cell lung cancer (NSCLC). The authors found that continuing nivolumab beyond a fixed duration of 1-year may improve patient outcomes.  Some background NSCLC is the most common form of lung cancer....

Read More

Evaluating the risk of heart-related side effects in patients treated with immune checkpoint inhibitors

Evaluating the risk of heart-related side effects in patients treated with immune checkpoint inhibitors

Posted by on Dec 31, 2020 in Lung cancer | 0 comments

In a nutshell This study evaluated the risk of heart-related (HR) side effects in patients with lung cancer treated with immune checkpoint inhibitors (ICI). Patients with lung cancer were shown to have a higher risk of developing HR side effects when treated with ICIs. Some background ICIs are a type of cancer therapy used to treat a wide variety of...

Read More